PT  - JOURNAL ARTICLE
AU  - Nguyen, Anthony
AU  - Khafagy, Rana
AU  - Hashemy, Habiba
AU  - Kuo, Kevin H.M.
AU  - Roshandel, Delnaz
AU  - Paterson, Andrew D.
AU  - Dash, Satya
TI  - Investigating the association between fasting insulin, erythrocytosis and HbA1c through Mendelian randomization and observational analyses
AID  - 10.1101/2022.12.21.22283813
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.21.22283813
4099  - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283813.short
4100  - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283813.full
AB  - Background Insulin resistance (IR)/hyperinsulinemia (HI), are early abnormalities in the etiology of prediabetes (preT2D) and type 2 diabetes (T2D). IR/HI also associate with increased erythrocytosis. Hemoglobin A1c (HbA1c) is commonly used to diagnose and monitor preT2D/T2D, but can be influenced by erythrocytosis independent of glycemi.Methods We undertook bidirectional Mendelian randomization (MR), in individuals of European ancestry, to investigate potential causal associations between increased fasting insulin adjusted for BMI (FI), erythrocytosis and its non-glycemic impact on HbA1c. We investigated the association between Triglyceride-glucose index (TGI), a surrogate measure of IR/HI, and glycation gap (difference between measured HbA1c and predicted HbA1c derived from linear regression of fasting glucose) in people with normoglycemia and preT2D.Results Inverse variance weighted MR (IVWMR) suggests increased FI increases haemoglobin (b=0.54+/-0.09, p=2.7 × 10-10), red cell count (RCC, b=0.54+/-0.12, p=5.38×10-6) and reticulocyte (RETIC, b=0.70+/-0.15, p=2.18×10-6). Multivariable MR indicates increased FI does not impact HbA1c (b=0.23+/-0.16, p=0.162) but reduces HbA1c after adjustment for T2D (b=0.31+/-0.13, p=0.016). Increased haemoglobin (b=0.03+/-0.01, p=0.02), RCC (b=0.02+/-0.01, p=0.04) and RETIC (b=0.03+/-0.01, p=0.002) might modestly increase FI. Increased TGI associates with decreased glycation gap, i.e. measured HbA1c was lower than expected based on fasting glucose, (b=-0.09±0.009, p<0.0001) in people with preT2D but not in normoglycemia (b=0.02±0.007, p<0.0001).Conclusions MR suggests increased FI increases erythrocytosis and might potentially decrease HbA1c by non-glycemic effects. Increased TGI, a surrogate measure of increased FI, associates with lower-than-expected HbA1 in people with preT2D. These findings merit confirmatory studies to evaluate its clinical significance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSD is funded by CIHR, Heart & Stroke Foundation of Canada and Banting & Best Diabetes Centre (DH Gales Family Charitable Foundation New Investigator Award and a Reuben & Helene Dennis Scholar in Diabetes Research).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For our primary analysis we undertook bidirectional inverse variance weighted (IVW) MR with FI as exposure (Supplementary File 3) and Hb, red cell count (RCC), reticulocyte count (RETIC) as outcomes. A p value of <0.05 was considered significant for primary and secondary analyses. We followed the recently published STROBE-MR reporting guidelines (Checklist in Supplementary File 2)(26). As we used publicly available summary statistics from GWAS, we did not seek institutional approval. Informed consent was obtained from the investigators from each participant in the original study Observational Study We received institutional approval from UHN research ethics board for the observational study. As we analyzed anonymized data, we did not obtain consent from individual patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript